Research Center Department, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia.
Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Immunol Invest. 2022 May;51(4):947-962. doi: 10.1080/08820139.2021.1887888. Epub 2021 Mar 4.
This systematic review and meta-analysis aimed to identify deferentially expressed serum miRNAs in multiple sclerosis patients and to evaluate their diagnostic value in multiple sclerosis diagnosis. Studies were identified on PubMed, Google scholar and Saudi digital library up to 30 September 2019. Articles that examined miRNA expression level in MS patients compared to healthy control group were included in the review and the data were extracted by three independent author. The comprehensive Meta-Analysis version 3 software was used for meta-analysis and heterogeneity of studies was identified according to I2 value. Our literatures search identified 9 eligible articles concerning the serum miRNA as a diagnostic biomarker for multiple sclerosis in comparison to healthy control group. 19 serum miRNAs differentially expressed in MS patients were identified (8 downregulated, 11 upregulated and 1 with discordant result). In publications that provided information on specific miRNA diagnostic value, the pooled AUC was 72% (95% CI 0.65-0.78, -value 0.00) for the overall multiple sclerosis patients and primary progressive MS (PPMS) (95% CI 0.66-0.78 -value 0.00). A miRNA panel of four miRNAs showed high sensitivity (73%) and specificity (68%) in distinguishing multiple sclerosis from control groups. When using single miRNA (miR-145), the sensitivity increased to 79% and the specificity to 87%. The available data from the literature and this meta-analysis suggests the potential use of serum miRNA as biomarkers for early diagnosis of MS with high sensitivity and specificity in distinguishing multiple sclerosis subtypes from healthy controls.: MS: Multiple sclerosis; IDD: inflammatory demyelinating diseases; RRMS: relapsing-remitting Multiple sclerosis; PPMS: primary progressive Multiple sclerosis; SPMS: secondary progressive Multiple sclerosis; NMO: Neuromyelitis optica; miRNA: microRNA; ECmiRNA: extracellular microRNA; AUC: Area Under the Curve; ROC: Receiver Operator Characteristic.
这篇系统综述和荟萃分析旨在鉴定多发性硬化症患者中差异表达的血清 miRNA，并评估其在多发性硬化症诊断中的诊断价值。研究人员在 PubMed、Google Scholar 和沙特数字图书馆上进行了检索，检索时间截至 2019 年 9 月 30 日。本综述纳入了比较多发性硬化症患者和健康对照组之间 miRNA 表达水平的研究，并由三位独立的作者提取数据。使用 Comprehensive Meta-Analysis version 3 软件进行荟萃分析，并根据 I²值确定研究的异质性。我们的文献检索确定了 9 篇关于血清 miRNA 作为多发性硬化症与健康对照组比较的诊断生物标志物的相关文章。鉴定出 19 种在 MS 患者中差异表达的血清 miRNA（8 种下调，11 种上调，1 种结果不一致）。在提供特定 miRNA 诊断价值信息的出版物中，总体多发性硬化症患者和原发性进展型多发性硬化症（PPMS）的汇总 AUC 为 72%（95%CI 0.65-0.78，- 值 0.00）。四种 miRNA 的 miRNA 组合在区分多发性硬化症与对照组方面具有较高的敏感性（73%）和特异性（68%）。当使用单个 miRNA（miR-145）时，敏感性增加到 79%，特异性增加到 87%。文献中的数据和本荟萃分析表明，血清 miRNA 作为生物标志物具有早期诊断多发性硬化症的潜力，具有较高的敏感性和特异性，可区分多发性硬化症亚型和健康对照者。: MS: 多发性硬化症；IDD: 炎症性脱髓鞘疾病；RRMS: 复发缓解型多发性硬化症；PPMS: 原发性进展型多发性硬化症；SPMS: 继发性进展型多发性硬化症；NMO: 视神经脊髓炎；miRNA: microRNA；EC miRNA: 细胞外 microRNA；AUC: 曲线下面积；ROC: 受试者工作特征曲线。
